Cas no 51095-85-3 (2,7-Dihydrohomoerysotrine)
2,7-Dihydrohomoerysotrine Chemical and Physical Properties
Names and Identifiers
-
- 2H,4H-Indolo[7a,1-a][2]benzazepine,1,5,6,11,12,- 13-hexahydro-8,9,12-trimethoxy-,(10bS,- 12S)-
- 2,7-Dihydrohomoerysotrine
- AC1L6PRX
- B602425K094
- CHEMBL487209
- NSC166069
- NSC-166069
- W1132
- (1S,17S)-4,5,17-trimethoxy-11-azatetracyclo[9.7.0.01,14.02,7]octadeca-2,4,6,14-tetraene
- Homoerysotrine,2,7-dihydro-
- NSC 166069
- DTXSID60304511
- AKOS032948726
- FS-9944
- C-Homoerythrinan,6-didehydro-3,15,16-trimethoxy-, (3.beta.)-
- CS-0017343
- 51095-85-3
- HY-N1681
- [ "" ]
- (1S,17S)-4,5,17-trimethoxy-11-azatetracyclo(9.7.0.01,14.02,7)octadeca-2,4,6,14-tetraene
- DTXCID90255643
- (1S,17S)-4,5,17-TRIMETHOXY-11-AZATETRACYCLO[9.7.0.0(1),(1)?.0(2),?]OCTADECA-2,4,6,14-TETRAENE
- DA-49282
-
- Inchi: 1S/C20H27NO3/c1-22-16-7-6-15-8-10-21-9-4-5-14-11-18(23-2)19(24-3)12-17(14)20(15,21)13-16/h6,11-12,16H,4-5,7-10,13H2,1-3H3/t16-,20-/m0/s1
- InChI Key: VFNBFPRWBICVGZ-JXFKEZNVSA-N
- SMILES: O(C([H])([H])[H])[C@@]1([H])C([H])([H])C([H])=C2C([H])([H])C([H])([H])N3C([H])([H])C([H])([H])C([H])([H])C4=C([H])C(=C(C([H])=C4[C@@]32C1([H])[H])OC([H])([H])[H])OC([H])([H])[H]
Computed Properties
- Exact Mass: 329.19900
- Monoisotopic Mass: 329.19909372g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 24
- Rotatable Bond Count: 3
- Complexity: 493
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 2
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 30.9
- XLogP3: 2.7
Experimental Properties
- Color/Form: powder
- PSA: 30.93000
- LogP: 3.22410
2,7-Dihydrohomoerysotrine Security Information
- Storage Condition:Store at room temperature, 2-8 ℃ is better
2,7-Dihydrohomoerysotrine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | TN2743-1 mg |
2,7-Dihydrohomoerysotrine |
51095-85-3 | 1mg |
¥2915.00 | 2022-04-26 | ||
| TargetMol Chemicals | TN2743-5 mg |
2,7-Dihydrohomoerysotrine |
51095-85-3 | 98% | 5mg |
¥ 4,040 | 2023-07-11 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | TN2743-1 mL * 10 mM (in DMSO) |
2,7-Dihydrohomoerysotrine |
51095-85-3 | 1 mL * 10 mM (in DMSO) |
¥ 13850 | 2023-09-08 | ||
| TargetMol Chemicals | TN2743-5mg |
2,7-Dihydrohomoerysotrine |
51095-85-3 | 5mg |
¥ 13500 | 2024-07-20 | ||
| A2B Chem LLC | AG28262-5mg |
2,7-Dihydrohomoerysotrine |
51095-85-3 | 97.5% | 5mg |
$777.00 | 2024-04-19 | |
| TargetMol Chemicals | TN2743-1 ml * 10 mm |
2,7-Dihydrohomoerysotrine |
51095-85-3 | 1 ml * 10 mm |
¥ 13850 | 2024-07-20 | ||
| TargetMol Chemicals | TN2743-5mg |
2,7-Dihydrohomoerysotrine |
51095-85-3 | 5mg |
¥ 13500 | 2024-07-24 | ||
| TargetMol Chemicals | TN2743-1 ml * 10 mm |
2,7-Dihydrohomoerysotrine |
51095-85-3 | 1 ml * 10 mm |
¥ 13850 | 2024-07-24 |
2,7-Dihydrohomoerysotrine Related Literature
-
1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
-
Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
-
Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
-
Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
-
Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
Additional information on 2,7-Dihydrohomoerysotrine
Comprehensive Overview of 2,7-Dihydrohomoerysotrine (CAS No. 51095-85-3): Properties, Applications, and Research Insights
2,7-Dihydrohomoerysotrine (CAS No. 51095-85-3) is a naturally occurring alkaloid compound that has garnered significant attention in pharmacological and biochemical research due to its unique structural properties and potential therapeutic applications. This compound belongs to the class of homoerythrina alkaloids, which are known for their complex bicyclic frameworks and bioactive characteristics. Researchers have explored its interactions with biological systems, particularly in the context of neurotransmitter modulation and enzyme inhibition, making it a subject of interest for modern drug discovery.
The molecular structure of 2,7-Dihydrohomoerysotrine features a fused ring system with a tetrahydroquinoline core, which contributes to its stability and binding affinity with target proteins. Recent studies highlight its potential role in central nervous system (CNS) disorders, aligning with the growing demand for novel neuroactive compounds. For instance, its structural similarity to other alkaloids like erysotrine has prompted investigations into its anti-inflammatory and analgesic properties, addressing trending topics such as natural pain management and alternative therapeutics.
In the realm of phytochemistry, 2,7-Dihydrohomoerysotrine is often extracted from specific plant species, including members of the Erythrina genus. This ties into the broader consumer interest in plant-derived bioactive compounds and sustainable sourcing, which are frequently searched topics in natural product research. Analytical techniques such as HPLC-MS and NMR spectroscopy are commonly employed to isolate and characterize this compound, ensuring high purity for experimental use.
From a commercial perspective, 2,7-Dihydrohomoerysotrine is utilized in pharmaceutical intermediates and reference standards, catering to laboratories focused on drug development and quality control. Its CAS No. 51095-85-3 serves as a critical identifier in regulatory documentation and scientific literature, facilitating seamless cross-referencing in databases like PubChem and SciFinder. This underscores its importance in academic research and industrial applications.
Emerging trends in precision medicine and personalized therapeutics have further amplified the relevance of 2,7-Dihydrohomoerysotrine. Researchers are investigating its potential synergies with nanocarrier systems for targeted drug delivery, a hot topic in biomedical engineering. Additionally, its mechanism of action in cell signaling pathways is being explored, offering insights into conditions like neurodegenerative diseases and metabolic syndromes.
To conclude, 2,7-Dihydrohomoerysotrine (CAS No. 51095-85-3) represents a multifaceted compound with promising applications across pharmacology, biotechnology, and material science. Its study aligns with contemporary scientific inquiries into bioactive natural products and green chemistry, ensuring its continued relevance in both academic and industrial settings. Future research may uncover additional functionalities, solidifying its position as a valuable asset in molecular science.
51095-85-3 (2,7-Dihydrohomoerysotrine) Related Products
- 87340-25-8(Fortuneine)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)